With the approval of the first biosimilar product in the United States this year, cost containment pressures and a pending patent cliff, Pharma IQ takes a closer look at the current biosimilars market.
Download PDF Attachment
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
April 20-21, 2026
The Logan, Philadelphia, USA
Register Now |
View Agenda |
Learn More